Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

Key Takeaways AngioDynamics delivered stronger-than-expected Q4 revenue and a narrower adjusted loss per share.NanoKnife drives growth with FDA clearance, rising disposable sales, and future reimbursement catalysts.Auryon, AlphaVac, and AngioVac growth plus steady legacy products support a resilient revenue base.AngioDynamics (ANGO) has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid fourth-quarter fiscal 2025 performance, ...